Summary

Location
at Los Angeles, California and other locations
Dates
study started
completion around
Principal Investigator
by Jaime Deville

Description

Summary

The study will explore the effects of early intensive antiretroviral therapy (ART) with or without a broadly neutralizing antibody (bNAb) on achieving HIV remission (HIV RNA below the limit of detection of the assay) among infants living with HIV.

Official Title

Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study

Details

Keywords

HIV Infection, HIV Remission, HIV Infections, Ritonavir, Lopinavir, Raltegravir Potassium, Nevirapine, Reverse Transcriptase Inhibitors, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Nevirapine (NVP), Lopinavir/Ritonavir (LPV/r), Raltegravir (RAL), VRC01, DTG, VRC07-523LS

Eligibility

Locations

  • 5112, David Geffen School of Medicine at UCLA Clinical Research Site accepting new patients
    Los Angeles California 90095-1752 United States
  • 5048, University of Southern California Clinical Research Site accepting new patients
    Los Angeles California 90089 United States

Lead Scientist at UCLA

  • Jaime Deville
    HS Clinical Professor, Pediatrics, Medicine. Authored (or co-authored) 56 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Links
Related Info
ID
NCT02140255
Phase
Phase 1/2 HIV/AIDS Research Study
Study Type
Interventional
Participants
Expecting 1120 study participants
Last Updated